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CLINICAL RESEARCH Acute Coronary Syndromes 
Ticagrelor Increases Adenosine Plasma 
Concentration in Patients With an 
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Franck Paganelli, MD, PHD,* Françoise Dignat-George, MD, PHD,y{ Regis Guieu, MD, PHDz# 
Marseille, France 
Objectives This study aimed to investigate the impact of ticagrelor on adenosine plasma concentration (APC) in acute coronary 
syndrome (ACS) patients. 
Background Ticagrelor is a direct-acting P2Y12-adenosine diphosphate receptor blocker. The clinical beneﬁt of ticagrelor 
compared with clopidogrel in ACS patients suggests that the drug has non–platelet-directed properties. Animal 
and in vitro models suggested that the “pleiotropic” properties of ticagrelor may be related to an interaction with 
adenosine metabolism. 
Methods We prospectively randomized 60 ACS patients to receive ticagrelor or clopidogrel. The APC was measured by liquid 
chromatography. To assess the mechanism of APC variation, we measured adenosine deaminase concentration, 
adenosine uptake by red blood cells, and cyclic adenosine monophosphate production by cells overexpressing 
adenosine receptors. The P2Y12-adenosine diphosphate receptor blockade was assessed by the vasodilator-
stimulated phosphoprotein index. 
Results Patients receiving ticagrelor had signiﬁcantly higher APC than patients receiving clopidogrel (1.5 mM [interquartile 
range: 0.98 to 1.7 mM] vs. 0.68 mM [interquartile range: 0.49 to 0.78 mM]; p < 0.01). The APC was not correlated 
with vasodilator-stimulated phosphoprotein (p ¼ 0.16). Serum-containing ticagrelor inhibited adenosine uptake by 
red blood cells compared with clopidogrel or controls (p < 0.01 for both comparisons). Adenosine deaminase 
activity was similar in serum of patients receiving clopidogrel or ticagrelor (p ¼ 0.1). Ticagrelor and clopidogrel had 
no direct impact on adenosine receptors (p ¼ not signiﬁcant). 
Conclusions Ticagrelor increases APC in ACS patients compared with clopidogrel by inhibiting adenosine uptake by red blood 
cells.     ( 
Ticagrelor is a direct-acting and reversible P2Y12-adenosine 
diphosphate (ADP) receptor blocker that has demonstrated 
higher biological efﬁcacy than clopidogrel (1). Its higher 
potency led to improved prognosis in acute coronary 
syndrome (ACS) patients (2). Interestingly, unlike in 
previous trials of P2Y12-ADP receptor blockers, in the 
PLATO (Platelet Inhibition and Patient Outcomes) trial 
the beneﬁt of ticagrelor has continued to grow, and cardio-
vascular mortality has been signiﬁcantly reduced (2–4). 
These observations led to the hypothesis that ticagrelor has 
pleiotropic properties and suggested some novel nonplatelet-
directed mechanisms of action. 
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Adenosine is released in the plasma by endothelial cells 
and myocytes during ischemia, hypoxia, or oxidative stress 
(5,6). Most of the plasma adenosine is quickly taken up 
by red blood cells (RBC) through a facilitated diffusion 
transport system (7) or converted into inosine by adenosine 
deaminase activity (ADA) (8). An increase in APC may, 
therefore, result from the inhibition of RBC uptake, reduced 
ADA, or both. Increased APC impacts the cardiovascular 
system by purinergic receptors, named A1, A2A, A2B, or A3 
depending on their pharmacological properties (9). 
In experimental studies, ticagrelor has been shown to 
increase adenosine-induced physiological response by shifting 
the dose-response curve for adenosine-induced coronary 
blood ﬂow velocity to the left (10). In addition, in vitro 
uptake by human RBC (11). However, these observations 
were made in a dog model and in vitro. Therefore, we aimed to 
investigate in ACS patients the effects of ticagrelor on APC. 
Methods 
We performed a single-center, prospective, open-label, 
randomized trial enrolling patients with intermediate- or 
high-risk non–ST-segment elevation ACS. Twenty healthy 
subjects without medication (12 men and 8 women) from 
our medical staff served as control group. 
review board and agrees with the declaration of Helsinki. All 
patients gave informed consent. They were randomly allo-
cated to ticagrelor or clopidogrel according to a sequence 
generated using R software (blockrand package, R Foun-
dation for Statistical Computing, Vienna, Austria). 
Blood samples were collected before coronary angiog-
raphy and 6 h after a P2Y12-ADP receptor antagonist 
loading dose. 
grelor group, and a loading dose of 600 mg clopidogrel 
followed by 75 mg daily was used in the clopidogrel group. 
In addition, all patients received a loading dose of 250 mg 
aspirin followed by 75 mg daily. 
Exclusion criteria were New York Heart Association 
a P2Y12-ADP receptor antagonist for <1 month, a platelet 
count <100 g/l, history of bleeding diathesis, history of 
hemorrhagic stroke, stroke in the preceding year, recent 
surgery (preceding month), use of medication having known 
interference with ticagrelor, and bradycardia. 
Stago, Asnières, France) (12). The VASP index was calculated 
from the mean ﬂuorescence intensity (MFI), assessed by ﬂow 
(PG) E1 or PGE1 and ADP 
according to the following for-mula: 
VASP ¼ [(MFI(PGE1) 1 
MFI(PGE1þADP)) / MFI(PGE1)]
                                                             
100. Patients with a VASP index 
                                                            
50% were considered to have high on-
treatment platelet reactivity (PR) (13). 
Adenosine plasma concentration 
measurement. Blood samples (3 ml) 
were collected and pro-cessed as 
described (14,15). Fresh whole blood 
was collected in tubes containing a 
stop solution 
The present study was approved by the institutional liquid chromatography, as previously described (14,15). 
Adenosine deaminase activity. Fresh serum was pipetted 
off after centrifugation of whole blood. The ADA was 
evaluated by the ammonium formed (Beckman DX, Beck-
man Coulter, Brea, California) after incubation (40 min at 
37C) of 125 ml serum with 750 ml adenosine (28 mM), as 
previously described (16). 
Adenosine uptake by RBC. Samples of fresh whole blood 
(1 ml) of patients and controls were collected on ethyl- 
For antiplatelet therapy, a loading dose of 180 mg tica-       enediaminetetraacetic acid tubes without stop solution. 
grelor followed by 90 mg twice-daily was used in the tica-       Then, 1 nmol of adenosine was added. Samples were 
continuously mixed with a vortex mixer for 60 s. Uptake by 
RBC was stopped by adding 500 ml cold stop solution 
at time 0 (T0) and after 15 s (T15), 30 s (T30), and 60 s 
(T60). Samples were immediately centrifuged (4C, 1,500g 
for 10 min), and APC was measured (15–17). 
functional class greater than or equal to III, cardiac arrest,       Adenosine receptor activity. To evaluate a potential 
contraindications to antiplatelet therapy, treatment with       adenosine receptor’s agonist property of ticagrelor or clopi- 
dogrel derivatives, we assessed the impact of the serum of 
patients on cyclic adenosine monophosphate (cAMP) 
production of recombinant cell lines overexpressing the A1 
or A2A receptor (CHO Chem 3 cells, Millipore, Billerica, 
Massachusetts). 
Vasodilator-stimulated phosphoprotein measurement. Cyclic AMP concentration determination. Fresh serum 
The vasodilator-stimulated phosphoprotein (VASP) index of patients and controls were pipetted off after centrifugation 
phosphorylation analysis was performed within 24 h of       of whole blood. No stop solution was used as adenosine is 
blood collection using platelet VASP kits (Diagnostica       quickly degradated by ADA, thus allowing assessment of 
the ability of drug derivatives to act on receptors. Modula-
tion of cAMP production by the patient’s serum was tested 
cytometry, of samples incubated with either prostaglandin and compared with serum controls and with serum 
Abbreviations 
and Acronyms 
ACS = acute coronary 
syndrome(s) 
ADA = adenosine deaminase 
activity 
ADP = adenosine 
diphosphate 
APC = adenosine plasma 
concentration 
cAMP = cyclic adenosine 
monophosphate 
MFI = mean ﬂuorescence 
intensity 
experiments suggested that ticagrelor inhibited adenosine re- to prevent RBC uptake and PG = prostaglandin 
RBC = red blood cells 
VASP = vasodilator- 
degradation of adenosine by PR = platelet reactivity 
ADA. The stop solution is re- 
quired to prevent adenosine deg- 
radation, which is very quick stimulated phosphoprotein 
otherwise. The stop solution was 
composed of dipyridamole, 0.2 mM; ethylenediaminetetra-
acetic acid disodium, 4 mM; erythro-9-(2-hydroxy-3-nonyl 
adenine), 5 mM; alpha,beta-methyleneadenosine 50-diphos-
phate, 79 mM; 20-deoxycoformycin, 10 mg/ml; and heparin 
sulfate, 1 IU/ml. After centrifugation, supernatants were 
deproteinized, and APC was measured by high-performance 
 
containing cyclopentyladenosine (CPA), an A1 receptor 
agonist, or CGS21680, an A2A receptor agonist, in a nano-
molar concentration. The cAMP concentration was deter-
mined by immunoassay (cAMP Biotrak EIA, Amersham, 
Orsay, France), as previously described (18). 
C-reactive protein. To evaluate a potential link bet-
ween inﬂammation and adenosine metabolism, we measured 
C-reactive protein (CRP) using Beckman DX apparatus. 
Clinical endpoints. Major adverse cardiovascular events, 
including cardiovascular death, myocardial infarction, urgent 
revascularization, and stroke at 1 month, were recorded. 
Bleeding was measured using the TIMI (Thrombolysis In 
Myocardial Infarction) study classiﬁcation. Dyspnea was 
also recorded. 
Statistical analysis. Analyses were performed with R free 
Computing). Continuous variables are expressed as mean SD or 
median and interquartile range (IQR). They were compa-red 
using the nonparametric Mann-Whitney U test. The 
nonparametric Wilcoxon test was used for intraindividual 
comparisons. Multiple comparisons were made among the 
4 groups using the multiple comparisons Mann-Whitney 
U test with Bonferroni corrections. Spearman’s r coefﬁcient 
of correlation was used for correlation studies. 
Results 
The baseline characteristics of the study population are given 
in Table 1. 
APC after P2Y12-ADP receptor loading dose. The APC 
was more than 2-fold higher in patients taking ticagrelor 
than in patients taking clopidogrel (1.5 mM [IQR: 0.98 to 
1.7 mM] vs. 0.68 mM [IQR: 0.49 to 0.78 mM]; p < 0.01) or 
controls (0.6 mM [IQR: 0.5 to 0.8 mM]; p < 0.01) (Fig. 1). 
No statistical difference was observed between patients 
under clopidogrel and controls. 
software, version 2.8.1 (R Foundation for Statistical Mechanism of APC increase. EFFECTS OF PATIENTS’ 
SERUM ON ADA. The patients in the 2 treatment groups did 
not differ signiﬁcantly regarding ADA (p ¼ 0.1). The ADA 
was higher in serum of patients in the ticagrelor group and 
clopidogrel group (15 IU [IQR: 12.6 to 18.2 IU] and 13.5 
IU [IQR: 12 to 16 IU], respectively) than in control subjects 
Table 1 Baseline Characteristics of Study Population 
Ticagrelor (n ¼ 30) 
62  12 23 
(76.7) 27.8  
5.1 
Clopidogrel (n ¼ 30) 
64  12 22 
(73.3) 27.6  
4.6 
p Value 
0.5 
0.9 
0.8 
9 (30) 
17 (56.7) 
11 (36.7) 
15 (50) 
7 (23.3) 
7 (23.3) 
21 (70) 
12 (40) 
16 (53.3) 
5 (16.7) 
0.8 
0.5 
0.9 
0.9 
0.6 
1 19 (63.3) 
11 (36.7) 
19 (63.3) 
11 (36.7) 
10 (34.5) 
7 (24.1) 
8 (27) 
12 (40) 
10 (34.5) 
14 (46.7) 
10 (34.5) 
12 (40) 
1 
0.1 
0.6 
1 
0.8 14 (46.7) 
7 (23.3) 
9 (30) 
8 (26.7) 
13 (43.3) 
9 (30) 
Age, yrs 
Male 
Body mass index, kg/m2 
Cardiovascular risk factors 
Smoking 
Hypercholesterolemia 
Diabetes mellitus 
Hypertension 
Family history of CAD 
Clinical setting 
NSTEMI 
Unstable angina 
Medication on admission 
Proton pump inhibitor 
Aspirin 
Beta-blocker 
Statin 
Angiography and intervention 
Number of diseased vessels 
1 
2 
3 
Biology 
Leukocytes, g/l 
Hemoglobin, g/dl 
Platelets, 103/l 
Fibrinogen, g/l 
Creatinine, mmol/l 
CRP, mg/l 
VASP index, % 
9.4  3.3 
14  1.8 
247  64 
3.6  1 90  
24 12.3  
18 
16.5  15 
8.6  2.8 
13.8  19 
243  44 
3.6  0.8 
89  27 17  
20 
46.9  22.3 
0.4 
0.7 
0.7 
0.9 
0.8 
0.4 
<0.0001 
Values are mean  SD or n (%). 
CAD ¼ coronary artery disease; CRP ¼ C-reactive protein; NSTEMI ¼ non–ST-segment elevation myocardial infarction; VASP ¼ vasodilator-
stimulated phosphoprotein. 
  
(8 IU [IQR: 7.1 to 9 IU]; p < 0.01 for both groups) (Fig. 2). 
The ADA weakly correlated with CRP (r ¼ 0.47; p < 0.01) 
(Fig. 3). 
EFFECTS OF PATIENTS’ SERUM ON CAMP PRODUCTION. Re-
garding the production of cAMP by cells expressing the 
adenosine receptors, no difference was observed between 
serum of patients in the ticagrelor group and in the clopi-
dogrel group compared with controls (p ¼ 0.7 and p ¼ 0.1 
for A1 receptors, respectively; and p ¼ 0.6 and p ¼ 0.1 
for A2A receptors, respectively) (Fig. 4). 
EFFECTS OF PATIENTS’ SERUM ON ADENOSINE UPTAKE BY RBC. 
Ticagrelor signiﬁcantly inhibited adenosine uptake by RBC 
compared with clopidogrel (p < 0.001 at all times) and with 
controls (p < 0.001 at all times). Clopidogrel did not impact 
adenosine uptake by RBC compared with controls (p ¼ not 
signiﬁcant at all times) (Fig. 5). 
PR and relationship with APC. Ticagrelor induced 
a signiﬁcantly higher PR inhibition than clopidogrel, as 
measured by the VASP index, after P2Y12-ADP receptor 
loading dose (14.7% [IQR: 9.2% to 19.8%] vs. 44% [IQR: 
33.5% to 64.2%]; p < 0.001). The rate of patients with 
high on-treatment PR after ticagrelor loading dose was 
signiﬁcantly lower compared with clopidogrel loading dose 
(3% vs. 40%; p < 0.001). Finally, PR inhibition and 
adenosine plasma concentration were not correlated (r ¼ 
0.27; p ¼ 0.2). 
Clinical endpoints. No ischemic or bleeding events were 
recorded within 1 month. Dyspnea was present in 7 patients 
in the ticagrelor group and in 5 patients in the clopidogrel 
group (p ¼ 0.6). 
Discussion 
The present study is the ﬁrst to demonstrate a signiﬁcant 
increase in APC in ACS patients treated with ticagrelor 
compared with clopidogrel. In addition, we observed that 
this property of ticagrelor was related to the inhibition of 
adenosine uptake by RBC. These ﬁndings demonstrate that 
ticagrelor has signiﬁcant off-target properties in ACS 
patients through a direct action on APC. Finally, in line 
with previous studies, ticagrelor achieved a more potent PR 
inhibition compared with clopidogrel as measured by the 
VASP index (1). 
Figure 2 ADA of Serum-Containing Drugs 
Deoxycoformycin was used as adenosine deaminase activity (ADA) inhibition 
control value. *Indicates p < 0.01 control group versus ticagrelor or clopidogrel 
group. 
Figure 1 Comparisons of APC in Ticagrelor, Clopidogrel, 
and Control Groups 
*Indicates p < 0.01 for ticagrelor group versus control group or clopidogrel group. Figure 3 Correlation Between ADA and CRP 
APC ¼ adenosine plasma concentration. 
Correlation (Spearman’s r) between adenosine deaminase activity (ADA) and 
C-reactive protein (CRP). 
  
A previous investigation involving healthy volunteers 
suggested that ticagrelor increases an adenosine-induced 
physiological response by shifting the dose-response curve 
for adenosine-induced coronary blood-ﬂow velocity to the 
left (10). Accordingly, in an animal experiment, van Giezen 
et al. (11) observed that ticagrelor enhances adenosine-
mediated responses on coronary blood ﬂow. Furthermore, 
those researchers suggested that this effect may be related 
to the inhibition of adenosine uptake by RBC. Consistent 
with these preliminary ﬁndings, the present study demon-
strated that ticagrelor increased APC in ACS patients. 
Our study has several additional originalities. First, it was 
performed in ACS patients, and thus it accurately reﬂects 
the effect of ticagrelor in patients with ischemia and coro-
nary artery disease. Second, we compared ticagrelor with 
clopidogrel, unlike previous studies that used placebo as 
control value (10). Finally, we also focused on the mecha-
nism of APC increase. In the present study, this property of 
ticagrelor over APC was independent of P2Y12-ADP 
receptor blockade. The serum of patients treated with tica-
grelor had no direct effect on adenosine receptor A1 or A2A 
and did not affect ADA. Finally, we demonstrated that the 
serum of ACS patients treated with ticagrelor inhibited 
adenosine uptake by RBC, leading to the increase in APC 
similar to what was observed for dipyridamole (19,20). 
The present results suggest that the “pleiotropic” prop-
erties of ticagrelor could in part be mediated by the increased 
APC. Adenosine has multiple properties involving blood, 
vessels, and ischemic damage. First, it inhibits platelet 
aggregation through the activation of A2A     receptors. 
Second, several lines of evidence conﬁrmed the vasodilatory 
properties of adenosine on arterial beds (21). These prop-
erties could be related to the activation of low-afﬁnity A2A 
receptors through the increase in APC, as these receptors 
are strongly implicated in coronary blood ﬂow regulation 
(21,22). Accordingly, the APC level measured in the pre-
sent study in the ticagrelor group is compatible with the 
activation of the adenosine A2A low afﬁnity receptors (21). 
These properties of adenosine may be particularly important 
in the context of diseased vessels and hypoxia associated 
with ACS. However, the role of adenosine in protection of 
the ischemic heart remains controversial, and the long-term 
impact of high APC on coronary artery disease remains to 
be determined (23). 
Ticagrelor was shown to have speciﬁc side effects, brady-
cardia and dyspnea, which could also be triggered by APC 
increase (2). However, the present study was not powered 
to explore a link between APC and these side effects. 
Conclusions 
Ticagrelor is associated with a signiﬁcant increase in APC in 
ACS patients that is related to the inhibition of adenosine 
re-uptake by RBC. This property of ticagrelor on APC may 
be responsible for the so-called “pleiotropic” properties of 
the drug and may contribute to its side effects. 
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Figure 5 Effects of Drugs on Adenosine Uptake by RBC 
At all times, serum of patients receiving ticagrelor (solid squares) was associated 
with a higher adenosine plasma concentration compared with the serum of 
clopidogrel patients (open triangles) or control subjects (solid triangles). Open 
circles ¼ stop solution. *p < 0.001 ticagrelor group versus clopidogrel group. 
RBC ¼ red blood cells. 
Figure 4 Production of cAMP by Chem Cells Overexpressing 
A1 or A2A Receptors 
Production of cyclic adenosine monophosphate (cAMP) production in the presence 
of serum of patients treated with clopidogrel or ticagrelor or with serum control 
subjects was similar for the A1 and A2A receptors. Cyclopentyladenosine (CPA) 
inhibited, whereas CGS21680 increased, cAMP production. 
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